Comparative Pharmacology
Head-to-head clinical analysis: ROXICODONE versus TALWIN 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROXICODONE versus TALWIN 50.
ROXICODONE vs TALWIN 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with high affinity for mu-opioid receptors, also binding to kappa and delta receptors. It acts primarily on the central nervous system and gastrointestinal tract.
Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.
5-15 mg orally every 4-6 hours as needed for pain; immediate-release formulation. Maximum 60 mg total daily dose for opioid-naive patients.
50 mg orally every 3-4 hours as needed; maximum 600 mg per day.
None Documented
None Documented
3.5-5 hours for immediate-release; 4.5-5.5 hours for extended-release. Accumulation may occur with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 2-3 hours. In patients with hepatic impairment, half-life may extend to 5-8 hours; in renal impairment, minimal change, but active metabolite accumulation may occur.
Renal excretion: 70-80% as unchanged drug and metabolites (oxymorphone, noroxycodone); fecal: 10-20%.
Primarily renal (60-70% as unchanged drug and conjugates), with 20-30% biliary/fecal elimination. Approximately 5-10% excreted in feces via bile.
Category C
Category C
Opioid Analgesic
Opioid Analgesic